Red biotechnology

From May 15–16, 2026, the 3rd International Symposium “Frontiers in Skin Immunity” will bring leading experts in dermatology and immunology to Heidelberg. Organized by the SFB Transregio 156 “The Skin as Sensor and Initiator of Local and Systemic Immunity” and the Medical Faculty of Heidelberg University the meeting highlights advances in understanding skin immune responses and marks the conclusion of the consortium’s third funding period.

A new technique based on labelled sugar molecules is providing previously unknown insights into the inner ear. A study by the University of Konstanz and Charité-Universitätsmedizin Berlin shows that the cupula in the inner ear of zebrafish completely regenerates within approximately two months. These findings open up a new avenue for research into sudden hearing loss and acute disorders of the sense of balance.

The cities of Heidelberg and Mainz want to work closely together in the future: Their aim is to further develop the Neckar-Rhine-Main region as an international innovation and biotech region. To this end, Heidelberg Mayor Würzner and Mainz Mayor Haase signed a MoU at Heidelberg City Hall on Friday, April 24, 2026. Those responsible for the central innovation and development structures of both cities also took part in the signing.

Not only actual chronological age, but also individual aging at the molecular level is a key factor in the development of cancer. This was discovered by scientists at the DKFZ and the Saarland Cancer Registry. If the so-called “epigenetic clocks” indicate accelerated biological aging, the likelihood of a cancer diagnosis increases. This finding could help identify at-risk groups and make early detection screenings more targeted

Estrogen does more than regulate reproduction — it helps brain cells handle stress. When levels decline after menopause, this ability is reduced, and these hormonal changes are believed to contribute to the increased risk of Alzheimer’s disease in women. MPI-IE researcher María José Pérez Jiménez has received the Klaus Tschira Boost Fund to investigate why — and whether these cellular responses can be restored.​

Chronic infections cause long-term changes in key immune cells. T helper cells suppress their immune function to ensure their survival. New targets for vaccines and cancer immunotherapies.

A recent study published in the European Respiratory Journal provides important new insights into the early identification and monitoring of chronic obstructive pulmonary disease (COPD). The focus is on airway wall thickness as an imaging marker for structural remodeling processes in the lungs.

A team of researchers from the Department of Integrative Evolutionary Biology at the Max Planck Institute for Biology Tübingen has discovered that vitamin B12 plays a key role in transmitting behavioural memories across generations. The study shows for the first time how a nutrient from the diet can, without altering the genome, influence behaviour over multiple generations.

Desmoplastic small- and round-cell tumor is rare, aggressive, and difficult to treat. Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have comprehensively analyzed 30 tumors and identified potential personalized treatment options for nearly all patients. In some patients, new targeted approaches were able to halt the disease for a surprisingly long time.

Can Aztekin and his team have discovered how oxygen-sensing explains why amphibians regenerate limbs and mammals do not.

Photoimmunotherapy - 09/04/2026

Switching off tumours with light: how photons can be used to target prostate cancer

Prostate cancer is the most common cancer among men in Germany. Relapses and the harsh side effects of traditional treatments remain a major challenge, even with advanced surgical techniques. At the University of Freiburg, Dr. Wolf is pioneering the development of photoimmunotherapy. Photoimmunotherapy combines light, antibodies and a specialised dye to precisely target tumour cells - simultaneously 'waking up' the immune system.

For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that (BET) proteins help activate, so blocking BET proteins should slow tumor growth. In the lab, it often did. In patients, results were mostly disappointing: limited responses, significant side effects, and no clear way to predict which tumors would respond at all.